ADMA Biologics, Inc. Quarterly report pursuant to Section 13 or 15(d)

SUBSEQUENT EVENTS (Details) - USD ($) shares in Millions		3 Months Ended					9 Months Ended
SUBSEQUENT EVENTS (Details) - USD ($) shares in Millions	Oct. 25, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020
Subsequent Events [Abstract]
Gross proceeds from issuance of common stock		$ 8,213,602	$ 17,189,560	$ 41,912,515	$ 10,639,168	$ 88,704,039
Proceeds from issuance of common stock, net of offering expenses							$ 67,315,677	$ 99,343,207
Subsequent Event [Member]
Subsequent Events [Abstract]
Common stock shares sold under sale agreement (in shares)	57.5
Gross proceeds from issuance of common stock	$ 57,500,000
Proceeds from issuance of common stock, net of offering expenses	$ 53,900,000